Mithra announced the opening of the bankruptcy procedure of Mithra Pharmaceuticals.
- Mithra Pharmaceuticals continues negotiations with Gedeon Richter relating to the sale of all shares in Neuralis and Estetra held by Mithra Pharmaceuticals and specific assets of Mithra R&D relating to the manufacture of estetrol
- Deal with Richter is expected to be signed and completed as soon as reasonably possible
- Transaction won’t create any value for Mithra Pharmaceuticals holders
- Mithra CDMO and Novalon entities aren’t affected by the bankruptcy
- They are subject to separate reorganization proceedings, which should be extended until June 30, subject to court approval
- NOTE: June 4, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.